WBA - Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
2024-02-23 12:31:39 ET
Summary
- Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024.
- Company is already in the process of exploring the use of PRX012 for the treatment of patients with Alzheimer's Disease in the ongoing phase 3 ASCENT-2 study.
- The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031.
- BMS-986446 is being advanced in collaboration with Bristol-Myers Squibb with the big pharma having taken over the program going forward; Prothena received a $55 million milestone payment based off of it.
Prothena Corporation plc ( PRTA ) is gearing up to report an update on its ongoing phase 1 study, using PRX012 for the treatment of patients with Alzheimer's Disease [AD]. It is expected that a data update for this program, using this drug to treat this patient population, will be released in 2024. This is one reason why this program is moving along well and why investors should be interested in taking a look at this company....
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle